The original PRISAR consortium implemented an innovative approach using imaging technologies and hybrid fluorescence/radionuclide probes for surgical intervention in cancer treatment. That project resulted in the development of a hybrid probe for image-guided surgery as well as a variety of additional tools and instruments. Now, the EU-funded PRISAR2 project aims to continue this effort by developing new industrial monitoring technologies for the surveillance of cancer. This innovative imaging-based platform will increase the surveillance window to allow for optimal selection of treatment options over time, possibly avoiding surgery. The 'watch and wait' strategies will enable better study of the cancer's progression so that any risks to the patient can be minimised leading to a better clinical outcome.

Info at Cordis